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BOLERO-3: Study Design 
*Actual enrollment was 569. 
†Following a 4-mg/kg loading dose on day 1, cycle 1 (1 cycle = every 21 days).  
http://www.clinicaltrials.gov/ct2/show/NCT01007942?term=BOLERO3&rank=1. 
Endpoints 
Primary: Progression-free survival 
Secondary: Overall survival, overall response rate, time to deterioration of 
ECOG performance status, safety, duration of response, clinical benefit rate, 
and quality of life 
N = 572* 
•Locally advanced or metastatic 
HER2+ breast cancer  
•Prior taxane required 
•Trastuzumab (TRAS) resistance 
– Adjuvant: progression on or 
within 12 months of TRAS  
– Metastatic: progression within 
4 weeks of TRAS  
•Measurable disease only 
Therapy until progressive 
disease or intolerable 
toxicity 
Everolimus (5 mg PO daily) + 
vinorelbine (25 mg/m2 weekly) 
+ TRAS (2 mg/kg week†) 
(n = 284) 
Placebo (PO daily) + 
 vinorelbine (25 mg/m2 weekly) 
+ TRAS (2 mg/kg weekly*) 
(n = 285) 
Randomize 
1:1 
• Stratification by prior lapatinib use 
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Biomarker hypothesis:  
• Patients with activated 
PI3K/mTOR pathway are 
resistant to trastuzumab and 
are more likely to benefit from 
blockade of the signaling 
pathway by everolimus 
Biomarker Specimens and Analyses 
• Archival tumor samples were available for biomarker 
analysis from 283/569 patients (50% of ITT) 
– 80% from primary tumor 
• Statistics: Median PFS and 95% CI, Cox models HR 
and 95% CI, KM curves; Cox models adjusted for 
covariate imbalance, where required 
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Biomarker  Assay 
Evaluable 
Sample Size (n)  % ITT 
PTEN Immunohistochemistry 237 42 
PIK3Ca Sanger sequencing, exons 9 and 20 182 32 
pS6 Immunohistochemistry 188 33 
CI, confidence interval; ITT, intention-to-treat; HR, hazard ratio; KM, Kaplan-Meier; PFS, progression-free survival. 
Efficacy Is Comparable Between ITT and 
Biomarker-Evaluable Populations 
• Biomarker-evaluable population: Individuals with at least  
1 of 3 biomarkers with evaluable result (N = 262, 46% ITT) 
• Demographic and clinical characteristics were similar 








ITT EVE  284 196 30.4 (29.3, 35.6) 0.78  
(0.65, 0.96) ITT PBO  285 219 25.1 (23.9, 30.0) 
BM EVE 130 95  29.7 (24.2, 35.3) 0.88  
(0.67, 1.17) BM PBO 132 104 24.7 (23.1, 30.1) 
6 BM, biomarker-evaluable population; PBO, placebo. 
Patients with High pS6 May Derive More 
Benefit from Addition of Everolimus 
• Optimal high and low pS6 cut-
point selected as ≥ and < 75th 
percentile (histo-score = 160) 
• Marker-treatment interaction 
(P = 0.038) 
• Shorter median PFS in high 
pS6 subgroup treated with 
placebo 
• Median pS6 level shows little 
effect on treatment 
Subgroup n Events 
Median PFS, weeks  
(95% CI) HR (95% CI) 
EVE pS6 high 23 15 29.4 (18.1, 55.1) 0.48 (0.24, 0.96) 
  PBO pS6 high 22 20 17.1 (11.7, 24.0) 
EVE pS6 low 66 47 24.9 (23.6, 31.0) 
1.14 (0.77, 1.68)  
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Effect of PTEN Levels on Treatment 
Benefit from Addition of Everolimus 
Subgroup Therapy 
n 
(# of Events) 






Subgroups defined by low or normal PTEN level 
H-score  
≥ 50 
EVE 100 (72) 30.1 (24.3, 35.6) 0.97  
(0.71, 1.33) 
0.11 
PBO 108 (85) 30.0 (24.0, 35.4) 
H-score  
< 50 
EVE 15 (11) 41.4 (17.3, 66.9) 0.52  
(0.21, 1.26) PBO 14 (11) 23.7 (10.6, 25.1) 
Subgroups defined by optimal cut-point of PTEN level (20th %ile) 
H-score  
≥ 20th %ile 
EVE 89 (67) 30.1 (24.0, 35.3) 1.05  
(0.75, 1.45) 
0.01 
PBO 100 (78) 30.1 (24.0, 36.0) 
H-score  
< 20th %ile 
EVE 26 (16) 41.9 (24.0, 53.1) 0.41  
(0.20, 0.82) PBO 22 (18) 23.1 (12.1, 24.7) 
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*Treatment-biomarker interaction. 
PTEN optimal cut-point selected as ≥ and < 20th percentile. Histo-score = 100. 
• Median PFS gain is 18-19 weeks for the low PTEN subgroup 
Patients with Low PTEN May Derive More 
Benefit from Everolimus 
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• No significant marker-treatment interaction (P = 0.32) 
PIK3CA Mutations Did Not Significantly 
Affect Everolimus Treatment Benefit  
*Not evaluable due to small sample size/event number. 10 
Group Biomarker n Events 
Median PFS  
(95% CI) HR (95% CI) 
Everolimus PIK3Ca 
mutant 
15 9 5.52 (*) 
0.65* (0.29, 1.45) 
Placebo 21 19 6.74 (4.83, 7.59) 
Everolimus PIK3Ca 
wildtype 
69 51 6.83 (5.52, 8.18) 
0.98 (0.67, 1.44) 
Placebo 77 56 5.72 (5.22, 7.79) 
Conclusions 
• Observations are consistent with hypothesis that 
mTOR inhibitor attenuates PI3K pathway 
activation‒related trastuzumab resistance  
• Addition of everolimus may be most beneficial to 
patients with HER2+ advanced breast cancer with low 
PTEN or high pS6 levels 
– No clear benefit observed in patients with normal PTEN 
or low pS6 levels 
• The exploratory analysis is based on ~ 40% of ITT and 
limited number of PI3K/mTOR pathway biomarkers 





• PIK3Ca mutations and PTEN levels are being analyzed 
in additional samples; PTEN level by different scoring 
methods will be used as part of the sensitivity test of 
the signal 
• Analysis of the impact of ER/PR status on the benefit 
from everolimus therapy observed in the discussed 
marker-defined subpopulations when data from 
additional samples are available  
• Genetic analysis of a broad oncogene and tumor 
suppressor gene panel by next-generation 
sequencing on the archival tumor samples is ongoing 
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